In Vitro Study of [18F]F-FAPI-74 Feasibility in Vulvar Cancer

Launched by FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS · Apr 3, 2025

Keywords

ClinConnect Summary

This clinical trial is looking to understand how a specific protein, called FAP, is present in samples from women with vulvar squamous cell carcinoma, a type of skin cancer that affects the vulva. The study will use tissue samples taken from patients who have had surgery for this cancer at a hospital in Rome, Italy. Researchers will analyze these samples to see how well the imaging technique works to detect this protein, which could help in understanding and potentially treating vulvar cancer in the future.

To be eligible for this study, participants must be women diagnosed with invasive vulvar squamous cell carcinoma, with samples available from both the main tumor and any affected lymph nodes. It’s important that the samples are stored properly and are large enough for testing. Participants will not need to do anything extra since the study will use existing samples and information already collected during their treatment. Currently, the trial is not yet recruiting participants, so more information will be available as it gets closer to starting.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Patients with histologically confirmed diagnosis of invasive vulvar cancer with squamous cell histotype, both from primary tumour site and excised metastatic LNs.
• • Availability of both FFPE and OCT stored samples from each primary tumour site and (when available) from the corresponding metastatic groin lymph nodes.
• • Samples stored in sufficient quantity not to be completely exhausted by their use for this study.
• • Optimal stored sample
• • Available clinical and histopathological data
• Exclusion Criteria:
• • - Coexistence of primary tumours other than vulvar cancer